Akebia Therapeutics (AKBA) Gains from Investment Securities (2017 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Gains from Investment Securities of -$456000.0 for Q1 2026, down 194.19% year-over-year from $484109.6 in Q1 2025, and up 79.84% quarter-over-quarter from -$2.3 million in Q4 2025.
Akebia Therapeutics (AKBA) Gains from Investment Securities (2017 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Gains from Investment Securities for 4 consecutive years, with -$456000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Gains from Investment Securities fell 194.19% year-over-year to -$456000.0; the TTM figure through Mar 2026 stood at $2.8 million (up 6117.78% YoY), while the FY2025 annual figure was $3.1 million, up 839.09% from the prior year.
- Gains from Investment Securities rose to -$456000.0 in Q1 2026 per AKBA's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $7.0 million in Q2 2025 and bottomed at -$2.3 million in Q2 2024.
- Historically, Gains from Investment Securities has averaged $330222.2 across 3 years, with a median of -$155000.0 in 2025.
- On a YoY basis, Gains from Investment Securities climbed as much as 399.44% in 2025 and fell as far as 271.03% in 2025.
- Akebia Therapeutics' Gains from Investment Securities stood at $1.7 million in 2024, then plunged by 235.04% to -$2.3 million in 2025, then soared by 79.84% to -$456000.0 in 2026.
- Business Quant data shows AKBA's Gains from Investment Securities at -$456000.0 in Q1 2026, -$2.3 million in Q4 2025, and -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -566,000.00 |
| Jun 30, 2026 | -566,000.00 |
| Mar 31, 2026 | -456,000.00 |
| Mar 31, 2026 | -456,000.00 |
| Dec 31, 2025 | -2.26 Mn |
| Dec 31, 2025 | -2.26 Mn |
| Sep 30, 2025 | -1.46 Mn |
| Sep 30, 2025 | -1.46 Mn |
| Jun 30, 2025 | 6.98 Mn |
| Jun 30, 2025 | 6.98 Mn |
| Mar 31, 2025 | -155,000.00 |
| Mar 31, 2025 | -155,000.00 |
| Dec 31, 2024 | 1.68 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | 856,000.00 |
| Sep 30, 2024 | 856,000.00 |
| Jun 30, 2024 | -2.33 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | 129,000.00 |
| Mar 31, 2024 | 129,000.00 |